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Background: Although conventional MR imaging (MRI) is the most widely used non-invasive technique for
brain tumor grading, its accuracy has been reported to be relatively low. Advanced MR techniques, such as
perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), and magnetic resonance spectroscopy
(MRS), could predict neoplastic histology, but their added value over conventional MRI is still open to debate.
Methods: We prospectively analyzed 129 patients diagnosed with primary brain tumors (118 gliomas) classified as
low-grade in 30 cases and high-grade in 99 cases.
Results: Significant differences were obtained in high-grade tumors for conventional MRI variables (necrosis,
enhancement, edema, hemorrhage, and neovascularization); high relative cerebral blood volume values (rCBV),
low relative apparent diffusion coefficients (rADC), high ratio of N-acetyl-aspartate/creatine at short echo time
(TE) and high choline/creatine at long TE. Among conventional MRI variables, the presence of enhancement and
necrosis were demonstrated to be the best predictors of high grade in primary brain tumors (sensitivity 95.9%;
specificity 70%). The best results in primary brain tumors were obtained for enhancement, necrosis, and rADC
(sensitivity 98.9%; specificity 75.9%). Necrosis and enhancement were the only predictors of high grade in gliomas
(sensitivity 97.6%; specificity 76%) when all the magnetic resonance variables were combined.
Conclusions: MRI is highly accurate in the assessment of tumor grade. The combination of conventional MRI
features with advanced MR variables showed only improved tumor grading by adding rADC to conventional MRI
variables in primary brain tumors.
Keywords: Brain neoplasms, Magnetic resonance imaging, Magnetic resonance spectroscopy, Diffusion-weighted
MRI, Perfusion-weighted MRIBackground
Primary brain tumors constitute a heterogeneous group
that can be classified according to their histological type
and grade of malignancy. The World Health Organization
(WHO) classifies primary brain tumors into four different
grades of malignancy [1]. Histological tumor grading has
several drawbacks, one of which is the need for stereotac-
tic biopsy, an invasive procedure with a certain risk of* Correspondence: juanadan.guzman@salud.madrid.org
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article, unless otherwise stated.morbidity and mortality. In addition, this approach is sub-
ject to sampling error, and its results depend upon the
neuropathologist’s experience [2]. These limitations lend
support to research into non-invasive imaging techniques.
Although conventional Magnetic Resonance Imaging
(MRI) is an established technique for the characterization
of brain tumors, it is not completely reliable [3]. Perfusion
Weighted Imaging (PWI), diffusion-weighted imaging
(DWI), Magnetic Resonance Spectroscopy (MRS) could
provide additional information to conventional MRI, as
they better reflect histopathology findings [3,4].
The feasibility of PWI, DWI, and MRS for tumor grading
has been clearly proved [5-7]. However, their additionaled Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Frequency distribution of histological subtypes
of brain tumors
Histological subtype WHO grade No. Percentage




Oligodendroglioma II 9 8.5%
III 2
PNET IV 7 5.4%
DNET I 2 1.6%
Hemangioblastoma I 1 0.8%
Neurocytoma II 1 0.8%
DNET, dysembryoplastic neuroepithelial tumor; PNET, primitive
neuroectodermal tumor.
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tional MRI has not yet been quantified.
The results obtained with different MR techniques are
contradictory, as shown for MRS and PWI with respect
to diagnostic accuracy in grading tumors [3,4,8-11]. Fur-
thermore, no significant differences have been found in
the assessment of tumor grade using advanced techniques
such as PWI [12], MRS [13,14], and DWI [9,15]. Although
a small number of studies compared these techniques, to
our knowledge only one published study has combined all
four in a single center [16].
We hypothesized conventional MRI could accurately
evaluate the grade of intraaxial brain tumors, and the
added value of other MRI techniques is very small. Our
aim was to quantify the improvement in diagnostic ac-
curacy resulting from the combination of conventional
MRI with PWI, DWI, and MRS.
Methods
The study population comprised 129 patients (71 men
and 58 women; mean age 52.7 years, range 11 to 84
years) diagnosed with primary brain tumors (the only
inclusion criterion) who were consecutively recruited be-
tween February 2004 and April 2009 at our institution.
The exclusion criteria were as follows: presence of non-
neoplastic brain masses; absence of histopathology data;
extensive hemorrhage that prevented evaluation by PWI,
DWI, and MRS; and previous surgical intervention,
chemotherapy, or radiotherapy.
The institutional research and ethics boards of Hospital
General Universitario Gregorio Marañón approved the
study, and all the patients gave their written informed
consent.
Tumor histology
The histology specimen was obtained by surgical resection
in 119 cases and by stereotactic biopsy in 10 cases and an-
alyzed by an expert neuropathologist with more than 30
years of experience blinded to radiological assessment.
Brain tumors were classified as aggressive high-grade tu-
mors (WHO grades III and IV) in 99 cases and low-grade
tumors (WHO grades I and II) in the remaining 30 pa-
tients (Table 1). We considered grades I and II as low-
grade tumors and grades III and IV as high-grade tumors
according to the differences in treatment and survival be-
tween groups: in general, high-grade tumors present lower
survival rates and need complementary therapy after sur-
gery (usually chemotherapy and radiotherapy), whereas in
low-grade tumors, survival is higher and the use of com-
plementary therapy remains open to debate.
In order to detect possible misclassifications of histo-
logical grading, three months after the end of recruitment
medical records were reviewed to determine survival, de-
fined as the time elapsed between MRI diagnosis anddeath or the last admission to our institution. No case of
disagreement was found between survival and tumoral
grade that indicates histological misclassifications.
Conventional MRI
All patients were prospectively examined using a 1.5T
MRI scanner (Intera or Achieva, Philips Healthcare, The
Netherlands). Sagittal T1-weighted images (647/15 ms
[TR/TE] SE) and coronal T2-weighted images (TR 4742/
TE, 100 ms; Turbo SE; Fluid-Attenuated Inversion Re-
covery (FLAIR), 11000/140/2800 ms [TR/TE/TI]) were
obtained with a 230-mm, Field Of View (FOV) and matrix
size of 512 × 512.
After intravenous administration of a double dose (0.2
mmol/kg) of gadobutrol 1.0 mmol/ml (Gadovist, Bayer
Schering Farma, Berlin, Germany), an axial T1-weighted
3D fast-field echo sequence was acquired (TR 16/TE 4.6
ms) with a flip angle of 8°, FOV of 256 × 256 mm, and
matrix size of 176 × 288.
Dynamic contrast-enhanced PWI
PWI was performed using a dynamic contrast-enhanced
T2*-weighted gradient echo. EPI- Echo planar images -EPI-
(single shot [TR 1678/TE 30 ms] with an EPI factor of 61,
flip angle of 40°, matrix size of 128 × 128, and FOV of 230
mm) were acquired during the first pass of the gadobutrol
bolus, which was injected intravenously using a 20-gauge
needle at a rate of 4.0 ml/sec.
A series of 40 acquisitions were performed at 1.7-second
intervals. The first acquisition was acquired before injec-
tion to establish baseline (precontrast) intensity.
The results were transferred to a PC workstation for
processing (ViewForum Workstation, release 5.1V1L2;
Philips Healthcare). The possible effect of tracer recircula-
tion or leakage due to the disruption of the blood–brain
barrier was considered in the mathematical model by
fitting a gamma-variate function to the observed 1/T2*
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automatically implemented by the workstation.
DWI
Diffusion-weighted images were obtained with axial multi-
slice single-shot EPI SE sequences as follows: TR 3745
ms/TE 120 ms; EPI factor, 61; matrix size, 128 × 128;
FOV, 230 mm; and diffusion gradient encoding in three
orthogonal directions. The images and Apparent Diffusion
Coefficient (ADC) maps were calculated using b values of
0 and 2500 s/mm2. ADC values were quantified using the
PC workstation mentioned above.
MRS
Single-voxel proton MRS was performed in 117 patients.
Twelve patients refused to undergo this technique be-
cause of the additional examination time involved. The
technique used was point-resolved spectroscopy (PRESS)
with a TR of 2000 ms and two different TEs (23/144 ms).
The measurement of each spectrum was repeated 128
times with a cycling-phase of 16 to improve the signal-to-
noise ratio.
The size (mean 8.34 cc, range 5.6 – 18.2 cc) and loca-
tion of the voxels of interest were established in order to
position the largest possible voxel within the solid tumor
area, with minimal contamination from the surrounding
non-tumor tissue and avoiding areas of necrosis, cysts,
or hemorrhage as much as possible. We selected single-
voxel MRS owing to its lower time requirements, which
enabled all the MR sequences to be performed in a sin-
gle session.
Spectra were analyzed using custom-designed software
[17]. Signal intensity of metabolic peaks, spectral posi-
tions, and decay constants were taken into consideration
in coupled metabolite peaks. Signals of Choline (Cho),
N-acetyl-aspartate (NAA), Creatine (Cr), Lipids (Lip), and
Lactate (Lact) were quantified. The same quantification
procedure was followed to analyze the water peak, al-
though, in this case, Hankel singular value decomposition
was not performed to suppress the water signal.
Definition of image variables
The five features evaluated by conventional MRI were
as follows: 1) Enhancement, defined as an increased
signal in T1-weighted sequences in the tumor after ad-
ministration of gadolinium; 2) Necrosis (and cystic ne-
crosis), identified as areas within the neoplasm with a
signal in T1- and T2-weighted images similar to that of
cerebrospinal fluid (on FLAIR images these areas may
be hyperintense, owing to excess protein content); 3)
Edema, defined as an area of homogenous high signal
on FLAIR sequences surrounding the tumor; 4) Neovas-
cularization, defined as the presence of tubular struc-
tures within the tumor showing flow-void patterns onT2-weighted images representing abnormal tumor ves-
sels; and 5) Hemorrhage, characterized by an area of
magnetic field distortion due to the paramagnetic blood
breakdown products on the EPI T2*-weighted images,
which were obtained in the first series of PWI before gado-
linium reached the cerebral parenchyma (Figures 1 and 2).
All five features were assessed dichotomously (presence
or absence).
The relative Cerebral Blood Volume (rCBV) was calcu-
lated using PWI (Figure 3) based on a region of interest
(ROI) centered on the highest tumor rCBV value in the
parametric map. This ROI was drawn as large as possible
in an attempt to include all voxels with the highest and
similar values of CBV. Unprocessed perfusion images and
conventional post-gadolinium T1-weighted MRI images
were used to ensure that ROIs were not placed over blood
vessels. Tumor CBV was normalized to contralateral white
matter CBV, on which an ROI of the same dimensions
was drawn.
The relative Apparent Diffusion Coefficient (rADC)
was calculated using DWI (Figure 3). Five different
round-shaped ROIs ranging from 9.1 mm2 to 9.7 mm2
were placed in the solid tumor area. A further five ROIs
with the same dimensions were placed in the contralat-
eral normal cerebral area. The rADC was defined as the
ratio of averaged ADCs between tumors and normal
areas [18].
The Cho/Cr, NAA/Cr, Cho/H2O, and NAA/H2O ratios
and the presence or absence of Lip or Lact were mea-
sured by MRS at long and short TE. We included the
water peak as an internal reference following previously
published data that report this approach to be a robust
method for standardization [19]. Metabolic peak positions
were assigned as follows: Cho, 3.22 ppm; Cr, 3.02 ppm;
NAA, 2.02 ppm; Lip, 0.5-1.5 ppm. Lact (1.33 ppm) was
identified as an inverted doublet at 144 ppm.
All variables obtained were assessed by consensus of
two expert neuroradiologists with more than 10 years of
experience (JG and PF).
Statistical analysis
In the univariate analysis, continuous variables were
assessed using the Mann–Whitney test and qualitative
variables using a two-tailed Fisher exact test.
A multivariate logistic regression model was applied to
assess the combined and independent values of predictor
variables. We used a forward stepwise selection proced-
ure with p-to-enter and p-to-remove value thresholds of
p < 0.05 and p > 0.01 and a cutoff value of 0.5. Sensitivity,
specificity, positive predictive value, negative predictive
value, and a Receiver Operating Characteristic (ROC)
curve were obtained for the predictor variables.
Statistical procedures were performed with SPSS version
13.0 (SPSS Inc, Chicago, Illinois, USA).
Figure 1 Example of MR images from a patient with glioblastoma (grade IV). a, Contrast-enhanced axial T1-weighted image shows an
enhancing mass in the right frontal region. b, Axial FLAIR image shows peritumoral edema. c, Coronal turbo SE T2-weighted image revealing
abnormal macroscopic vessels (arrows) within the tumor (neovascularization).
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Univariate analysis
The rCBV ratio could not be obtained in five patients
owing to magnetic susceptibility artifacts resulting from
an extensive tumor hemorrhage or a poor adjustment to
the gamma curve.Figure 2 Example of MR images of glioblastoma (grade IV). a-c, Signs of
on contrast-enhanced axial T1-weighted images (a) and hyperintensity on T2
as an area of hypointensity (arrow) due the paramagnetic blood breakdown pValues of rADC were not calculated in five patients
because of the presence of extensive necrosis. In this
situation, there was not enough solid area to place the
ROIs without partial volume effects in the necrotic region.
Quantitative MRS results were not taken into consider-
ation in 20 cases, owing to the poor quality of the spectra.necrosis, identified as regions within the neoplasm with hypointensity
-weighted images (b) and FLAIR images (c). d, Signs of hemorrhage seen
roducts on the axial EPI T2*-weighted images.
Figure 3 Example of PWI and DWI assessment in cases of glioblastomas (grade IV). a, Calculation of the rCBV ratio. The figure shows
the ROI location covering the maximal values of CBV (T) in the parametric map. A similar ROI was placed in the contralateral white matter to
normalize the image (N). This image corresponds to the conventional MRI images of Figure 1. b, Calculation of rADC. Example of five different
ROIs placed within the solid area of the tumor in the ADC map (represented by number 1) and in the contralateral healthy area (represented by
number 2). The MRI features of this case are shown in Figure 2.
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missed, because the internal references (Cho or H2O)
or the metabolite peaks of Cho and/or NAA could not
be measured.
The presence of the MRI features was significantly
greater in high-grade tumors (p < 0.0001). Statistically
significant differences were found in rCBV (p < 0.0001),
rADC (p < 0.0001), and the NAA/Cr (p = 0.005) ratio at
a short TE and in the Cho/Cr ratio (p = 0.008) at a long
TE (Table 2). The Lip peak was significantly present in
high-grade tumors (p < 0.0001) (Table 2). The variablesTable 2 Comparison of perfusion-weighted, diffusion-weighte
between low-grade and high-grade tumor groups
Low-grade tumor
Variable n Range Mean SD
rCBV 29 0.00-13.61 2.09 3.17
rADC 30 0.81-2.55 1.74 0.44
NAA/Cra 23 0.00-11.73 2.39 3.00
Cho/Crb 24 0.95-21.43 3.56 5.34
Lipids 26 N/A N/A N/A
NAA/Crb 24 0.00-11.61 1.53 2.28
Cho/Cra 23 0.07-9.30 2.00 2,13
Cho/H2O
a 19 3.02×10−4-5.88×10−3 6.60×10−4 1.29×10−3
NAA/H2O
a 20 0.00-3.28×10−3 6.67×10−4 7.85×10−4
Cho/H2O
b 17 2.10x10−4-3.98×10−3 8.39×10−4 9.00×10−3
NAA/H2O
b 18 0.00-1.01×10−3 3.12×10−4 2.74×10−3
Lactate 26 N/A N/A N/A
Cho, choline; Cr, creatine; NAA, N-acetyl-aspartate; N/A, not available (qualitative va
relative cerebral blood volume.
aTE = 23 ms.
bTE = 144 ms.enhancement and necrosis showed the highest Odds
Ratio (OR) for classifying high-grade tumors (55.42 and
23.82, respectively) (Table 3).
Combination of the variables obtained by conventional
MRI
The imaging features identified as independent predic-
tors of tumor grade were enhancement (OR, 23.37; 95%
Confidence Interval -CI, 5.85-93.25) and necrosis (OR,
9.04; 95% CI, 2.61 -31.25). The sensitivity and specificity
for the identification of high-grade tumors with thesed, and magnetic resonance spectroscopy variables
High-grade tumor
n Range Mean SD P Value
95 0.51-19.18 5.75 4.10 <0.0001
94 0.43-2.63 1.17 0.38 <0.0001
64 0.00-42.26 7.28 9.12 0.005
70 0.81-77.46 7.95 14.88 0.008
83 N/A N/A N/A <0.0001
71 0.00-20.36 1.49 3.15 NS
65 0.00-30.15 3.24 4.91 NS
63 0.00-6.18×10−3 4.21×10−3 8.03×10−4 NS
63 0.00-1.73×10−2 1.00×10−3 2.20×10−3 NS
64 4.74×10−4-8.27×10−3 8.34×10−4 1.23×10−3 NS
67 0.00-6.86×10−3 3.98×10−4 1,18×10−3 NS
83 N/A N/A N/A NS
riables); NS, not significant; rADC, relative apparent diffusion coefficient; rCBV,
Table 3 Odds ratios obtained from the univariate analysis
of the magnetic resonance variables with significant
differences between low-grade and high-grade tumor
groups
Variable OR 95% CI P value
Enhancement 55.42 15.58-197.15 <0.0001
Necrosis 23.82 8.43-67.35 <0.0001
Neovascularization 7.80 2.53-24.02 <0.0001
Edema 7.43 3.02-18.26 <0.0001
Hemorrhage 13.85 3.93-48.77 <0.0001
rCBV 1.68 1.23-2.19 <0.0001
rADC 0.05 0.01-0.16 <0.0001
NAA/Cra 1.21 1.03-1.42 0.02
Cho/Crb 1.05 0.97-1.14 0.22
Lipids 9.80 3.56-26.96 <0.0001
CI, confidence interval; OR, odds ratio; Cho, choline; Cr, creatine; NAA,
N-acetyl-aspartate; rADC, relative apparent diffusion coefficient; rCBV, relative
cerebral blood volume.
aTE = 23 ms.
bTE = 144 ms.
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(Table 4). The Area Under the receiver operating charac-
teristic Curve (AUC) was 0.890 (Figure 4).Combination of the variables obtained by conventional
MRI, PWI, DWI, and MRS
This multivariate logistic regression analysis identified
only enhancement (OR, 11.63; 95% CI, 2.35-58.82) and
necrosis (OR, 8.48; 95% CI, 1.95-37.04) as independent
predictors (Table 4). The sensitivity and specificity of these
variables in grading brain tumors was 98.2% and 46.7%,
respectively, and the AUC was 0.871. Thus, advanced vari-
ables seemed not to provide additional predictive value.
However, it is noteworthy that one or more variables wereTable 4 Variables with independent predictive value obtained





OR 95% CI P Coef
(β)
MRI 129
Enhancement 23.37 5.85-93.25 <0.0001 3.15
Necrosis 9.04 2.61-31.25 0.001 2,20
MRI
71
Enhancement 11.63 2.35-58.82 0.003 2.46
PWI
DWI Necrosis 8.48 1.95-37.04 0.005 2.13
MRS
MRI Enhancement 16.95 3.89-71.43 <0.0001 2.83
PWI 120 Necrosis 5.40 1.32-21.74 0.019 1.69
DWI rADC 0.22 0.50-0.97 0.045 −1.5
AUC, area under the receiver operating characteristic curve; CI, confidence interval;
spectroscopy; N, number of cases from which each classifier was constructed; PWI,
odds ratio; PPV, positive predictive value; NPV, negative predictive value.missing in 58 cases, thus considerably reducing the sample
size and the power of the analysis.
Combination of the variables obtained by conventional
MRI, PWI, and DWI
As most missing data corresponded to MRS, we conducted
another analysis excluding the MRS–related variables. In
this case, the number of cases remaining was 120, and the
variables identified as independent predictors of high-
grade tumors were enhancement (OR, 16.95; 95% CI,
3.89-71.43), necrosis (OR, 5.40; 95% CI, 1.32-21.74), and
low rADC values (OR,0.22; 95% CI, 0.50-0.97) (Table 4).
The sensitivity and specificity obtained with these three
variables were 98.9% and 75.9%, respectively. The AUC
was 0.923 (Figure 4).
Multivariate analysis of gliomas
As most tumors in our series (91.5%) were gliomas (astro-
cytoma and oligodendroglioma), the multivariate logistic
regression analysis was repeated in this histologic subtype.
Independently of the variables included in the analysis,
the only predictors of high grade were necrosis and en-
hancement, with a sensitivity of 97.6% and specificity of
76% when the conventional MRI, PWI, and DWI variables
were combined (Table 5).
Discussion
Conventional MRI constitutes the most used MRI tech-
nique in the assessment of primary brain tumors. However,
higher accuracy is necessary when grading brain tumors
[3,8]. Advanced MR techniques provide additional infor-
mation related to histological features of the tumor, as
grade of neovascularization, cellularity, and mitotic index
[10,20,21]. The validity of conventional and advanced MR













0.890 95.9 70 91.3 84
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0.81
0.871 98.2 46.7 87.3 87.5
0.77
0.75
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1 0.75
DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging; MRS, MR
perfusion-weighted imaging; rADC, relative apparent diffusion coefficient; OR,
Figure 4 Receiving operating characteristic curves of the combination of MR imaging features alone (a) or associated with PWI and
DWI parameters (b) for grading of primary brain tumors.
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the variables using all the MR techniques analyzed (con-
ventional MRI variables, rCBV, rADC, NAA/Cr at short
TE, Cho/Cr at long TE, and presence of lipids) were con-
sistent with those reported in the literature.
Few attempts have been made to combine different
MRI techniques in grading tumors [3,4,8,27] and, to our
knowledge, only the study by Yoon et al. [16] has com-
bined conventional MRI with PWI, DWI, and MRS in a
group of patients diagnosed with cerebral gliomas. That
study showed that there were no significant differences
in the diagnostic performances of any of those MRTable 5 Variables with independent predictive value obtained
techniques (multivariate logistic regression) in gliomas
Technique N Predictor
variables
OR 95% CI P Coe
(β)
MRI 118
Enhancement 58.82 9.35-333.33 <0.0001 4.06
Necrosis 13.89 2.91-66.67 0.001 2,63
MRI
67
Enhancement 25 3.60-166.67 0.001 2.46
PWI




Enhancement 50 8.13-333.33 <0.0001 3.94
PWI
DWI Necrosis 13.89 2.91- 66.67 0.001 2.64
AUC, area under the receiver operating characteristic curve; CI, confidence interval;
spectroscopy; N, number of cases from which each classifier was constructed; PWI,
odds ratio; PPV, positive predictive value; NPV, negative predictive value.imaging techniques. Recently, Caulo et al. [28] has also
analyzed the information provided by these advanced
MR techniques in the assessment of tumor grade in gli-
omas but, in their analysis, ADC maps were only used to
define different tumoral regions in order to guide ROIs’
placement. Thus, the ADC values were not calculated to
differentiate grade of aggressiveness. In our prospective
study, we analyzed a series of variables for conventional
MRI and advanced techniques (PWI, DWI, and MRS) to
determine whether a combination of techniques was bet-
ter than conventional MRI alone and, unlike in Caulo
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DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging; MRS, MR
perfusion-weighted imaging; rADC, relative apparent diffusion coefficient; OR,
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and necrosis, were the only predictors of grade in primary
brain tumors.
The fact that data were missing from our study (at
least one variable in 58 cases) could affect the statistical
power. However, excluding these cases—and including
only patients with all the variables—could lead to a se-
lection bias. The radiologist should analyze brain tumors
based on histological features (extensive necrosis or
hemorrhage) that impair evaluation with advanced MRI
techniques. For example, when necrosis was extensive,
the area of the solid part was much too small to calcu-
late advanced MR parameters [29,30]. Most published
articles obviate this situation by avoiding cases with at
least one missing data obtained by different MRI tech-
niques [3,4,8]. As missing data correspond to MRS in
most cases (56 cases), we performed an analysis combin-
ing all the variables except MRS data and found that at
least one item of data was missed in only 9 patients. As
a result, enhancement, necrosis, and low rADC were pre-
dictors of high tumor grade, and these variables provided
higher accuracy (sensitivity 98.9%; specificity 75.9%) than
those obtained with the other combinations analyzed (only
MRI variables or MRI, PWI, DWI, and MRS variables).
However, the improvement was no more than modest
compared with the results obtained by combining only
MRI variables (sensitivity 95.9%, specificity 70%).
Previous studies that analyzed differences between tumor
grades were limited to gliomas [3,4,8,31-33]. However, we
included all the primary brain tumors in order to mimic
conditions of clinical practice, in which the radiologist has
to provide a presumptive diagnosis of malignancy before
surgery, regardless of the histological type. In our series
8.5% of tumors were non-gliomas due to the lower fre-
quency of these type of tumors. Nevertheless, we repeated
the multivariate analysis including only gliomas, since these
were the most frequent histological subtype in our series.
Unlike other authors, we were unable to demonstrate any
additional value of advanced MR over conventional MRI
[3,8,34], possibly because of our approach in assessing
MRI. We showed high sensitivity and specificity (97.8%
and 76.9%, respectively) for necrosis and enhancement as
they were the best predictor variables of MRI in grading
gliomas based on the results of the multivariate analysis
combining conventional MRI variables. Using conventional
MRI criteria, other authors obtained lower values (sensitiv-
ity of 42.1%-93.3% and a specificity of 60%-75.0%), possibly
as a result of different selection criteria for high-grade MRI
criteria [3,4,8,31,32]. For example, signal heterogeneity of
the lesions could be related to other variables, such as
presence of hemorrhage or necrosis. Mass effect is inher-
ent to any tumor and is not necessarily associated with
the histological grade. Furthermore, the existence of ill-
defined borders is not useful in certain cases, such asglioblastomas, which could show well-defined borders on
MRI, and low-grade gliomas, which tend to have an infil-
trating appearance [35]. Some authors globally assessed
the MRI features without specifying the diagnostic value
of each of these imaging variables [3,4,22]. In addition, it
is important to note that studies with negative results are
less likely to be published, despite being well designed and
conducted [36] thus leading to publication bias and over-
estimation of the value of advanced MR techniques in pre-
vious studies.
Our study has several limitations. We performed
single-voxel MRS instead multivoxel MRS, which more
accurately assesses tumor heterogeneity [37]. However,
single-voxel studies have certain advantages, such as low
time requirements, quicker post-processing, and better
field homogeneity in the volume of interest [25]. The fact
that most missing data were spectroscopic variables could
lead us to underestimate the added value of MRS over
conventional MRI in grading brain tumors. The rADC
and rCBV ratios were calculated by selecting ROIs. As in
the case of single-voxel MRS, this approach may be prone
to sampling error, thus reinforcing the importance of care-
ful placement of the ROIs. To reduce the T1 leakage ef-
fects, we did not administer a preload of contrast agent.
Although this method seems to be the most robust for the
evaluation of brain tumors, a statistical validation has not
been provided [38]. In addition, to minimize the T1 and/
or T2 leakage effects [38], we applied a gamma-variate
function as a correction algorithm and the analysis of the
MR signal-intensity curves did not show in any case of
our series a rising of postbolus signal above the prebolus
baseline that indicates T1-leakage effect.
In our study, we have excluded patients with massive
hemorrhage. This criterion may be interpreted as contra-
dictory because we analyzed the presence of tumoral
hemorrhage by conventional MRI. However, we decided
not consider only that cases that could be interpreted as
brain hematomas secondary to brain tumors since the as-
sessment of all advanced MRI techniques in these patients
was not possible due to magnetic susceptibility artifacts
secondary to the big quantity of blood products.
The restricted size of our sample prevented us from
dividing it into training and validation sets, which would
constitute a more suitable design for our analysis. Conse-
quently, the accuracy we report in grading brain tumors
could be somewhat optimistic. Nevertheless, the conclu-
sions obtained by combining different MRI techniques
should remain unaffected. Our approach is widely re-
ported, thus making our results comparable [3,4,8,11,39].
Conclusions
Preoperative diagnosis of tumor grade by MRI could assist
in treatment planning, which is essential in cases were a
histological diagnosis cannot be made. Our work focuses
Guzmán-De-Villoria et al. Cancer Imaging  (2014) 14:35 Page 9 of 10on different types of primary brain tumors, since, in clin-
ical practice, tumor grade is analyzed using MRI with no
previous knowledge of histological type. An appropriate
analysis of conventional MRI features enables primary
brain tumors to be graded with high accuracy. The best
results for the prediction of high-grade tumors were ob-
tained by combining the variables enhancement, necro-
sis, and rADC. Only a slight improvement was obtained
with respect to conventional MRI criteria combined
with the only advanced MRI variable considered as pre-
dictive (rADC). No advanced MR variables seem to add
value to conventional MRI alone in the determination
of grade in gliomas.
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